Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA: Somatropin in Short Children Born Small for Gestational Age
NCT00191529Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2002
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Small for gestational age (SGA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in Height Standard Deviation Score at 2 years. Started Dec 2002; status: completed.
02
Drugs
somatropin
03
Conditions
Small for gestational age (SGA)
Beyond the preview
Go deeper on NCT00191529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191529.